Compare MDBH & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | NTRB |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 36.0M |
| IPO Year | 2022 | 2019 |
| Metric | MDBH | NTRB |
|---|---|---|
| Price | $2.93 | $5.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 32.5K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.45 | $2.80 |
| 52 Week High | $4.80 | $8.63 |
| Indicator | MDBH | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 77.22 |
| Support Level | $2.81 | $4.23 |
| Resistance Level | $3.22 | $6.41 |
| Average True Range (ATR) | 0.12 | 0.47 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 33.80 | 90.03 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.